CA3135388A1 - Pyrimidine jak inhibitors for the treatment of skin diseases - Google Patents

Pyrimidine jak inhibitors for the treatment of skin diseases Download PDF

Info

Publication number
CA3135388A1
CA3135388A1 CA3135388A CA3135388A CA3135388A1 CA 3135388 A1 CA3135388 A1 CA 3135388A1 CA 3135388 A CA3135388 A CA 3135388A CA 3135388 A CA3135388 A CA 3135388A CA 3135388 A1 CA3135388 A1 CA 3135388A1
Authority
CA
Canada
Prior art keywords
compound
acceptable salt
pharmaceutically
mmol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3135388A
Other languages
English (en)
French (fr)
Inventor
Philip A. GERKEN
Jianhua Chao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of CA3135388A1 publication Critical patent/CA3135388A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3135388A 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases Pending CA3135388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
US62/837,827 2019-04-24
PCT/US2020/029466 WO2020219640A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Publications (1)

Publication Number Publication Date
CA3135388A1 true CA3135388A1 (en) 2020-10-29

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3135388A Pending CA3135388A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Country Status (11)

Country Link
US (1) US11439641B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959213B1 (cg-RX-API-DMAC7.html)
JP (1) JP7482152B2 (cg-RX-API-DMAC7.html)
AR (1) AR118767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3135388A1 (cg-RX-API-DMAC7.html)
ES (1) ES2994097T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067909T2 (cg-RX-API-DMAC7.html)
PL (1) PL3959213T3 (cg-RX-API-DMAC7.html)
TW (1) TW202106681A (cg-RX-API-DMAC7.html)
WO (1) WO2020219640A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
AU2022270072A1 (en) 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
TWI740288B (zh) 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN115925705B (zh) 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药(上海)有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药(杭州)有限公司 一类jak激酶抑制剂及其制备和应用

Also Published As

Publication number Publication date
EP3959213C0 (en) 2024-06-05
US20200338073A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
AR118767A1 (es) 2021-10-27
JP7482152B2 (ja) 2024-05-13
US11439641B2 (en) 2022-09-13
EP3959213A1 (en) 2022-03-02
TW202106681A (zh) 2021-02-16
EP3959213B1 (en) 2024-06-05
WO2020219640A1 (en) 2020-10-29
PL3959213T3 (pl) 2024-11-04
HRP20241053T1 (hr) 2024-11-08
ES2994097T3 (en) 2025-01-17
HUE067909T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
US11845747B2 (en) Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
EP3959213B1 (en) Pyrimidine jak inhibitors for the treatment of skin diseases
US12172994B2 (en) Pyrimidine compound as JAK kinase inhibitor
CA3020506A1 (en) Pyrimidine compounds as jak kinase inhibitors
OA19911A (en) Pyrimidine compound as JAK kinase inhibitor.
HK40029509B (en) Pyrimidine compound as jak kinase inhibitor
HK40029509A (en) Pyrimidine compound as jak kinase inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250530

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260417

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625